Norwegian version of this page

Ane Gerda Zahl Eriksson

Professor II - Department of Gynaecological Oncology

Email a.g.z.eriksson@medisin.uio.no

Username

Visiting address Ullernchausséen 70 OUS Radiumhospitalet 0372 Oslo

Postal address Postboks 4950 Nydalen OUS, Rikshospitalet 0424 Oslo

Download business card

Associate Professor Ane Gerda Eriksson is a senior consultant at the Department of gynecologic cancer and head of the endometrial cancer and gynecologic sarcoma team at the Norwegian Radium Hospital.

Dr. Eriksson received her Medical Degree from the Medical University of Warsaw in Poland and completed residency training at Oslo University Hospital in Norway. She then completed fellowship in Gynecologic Oncology at Memorial Sloan Kettering Cancer Centre, New York, in 2015, and has since returned to the department of Gynecologic Oncology at the Norwegian Radium Hospital where she provides surgical and medical treatment for women with gynecologic malignancies.

Her principal area of clinical practice is advanced minimal invasive surgery for gynecologic cancers and radical procedures for advanced ovarian cancer. She holds a special interest in surgical education. She is an invited international speaker and educator, and is the founder and chair of the Advanced course in cytoreductive surgery for ovarian cancer organized at Oslo University Hospital.

Ane Gerda Eriksson defended her PhD on “Sentinel lymph nodes in endometrial carcinoma -Mapping, diagnostic accuracy and oncologic outcome” in 2018, and completed The Global Clinical Scholars Research Training Program at Harvard Medical School to further gain experience in design and implementation of clinical trials. Dr. Eriksson has a strong interest in clinical research. She takes part in ongoing collaborative trials at the Norwegian Radium Hospital and is a member of the Clinical Trials Unit of the Nordic Society of Gynecologic Oncology when she is the NSGO principal investigator/coordinator for the SENTICOL III trial. Dr. Eriksson has attracted competitive external funding from the Sister Institution Fund in collaboration with MD Andersen, and supervises master and PhD students at the University of Oslo, OSLOMET and NTNU. In her previous role as social media editor for the International Journal of Gynecologic Cancer she mentored numerous international editorial fellows. She is currently a mentor in the European Society of Gynecologic Oncology (ESGO) gender equity program.

Dr. Eriksson holds a special interest in image-guided surgery as well as molecular markers in endometrial cancer. She is currently investigating the implementation of sentinel lymph node biopsy in the South Western health region in Norway and has recently initiated a study exploring outcomes after fertility preservation in women with early stage cervical cancer and dysplasia. Dr. Eriksson is an active member of several national and international societies. She is currently a Council Member of ESGO.

Hagen, Kristine Krüger; Eyjolfsdottir, Brynhildur; Dahl, Gunn Fallås; Wang, Yun; Lund, Kjersti Vassmo & Nordskar, Nina Jebens [Show all 13 contributors for this article] (2026). Early post-operative complications after fertility-sparing surgery for cervical carcinoma: a retrospective study of a centralized national cohort of 127 consecutive women. International Journal of Gynecological Cancer. ISSN 1048-891X. doi: 10.1016/j.ijgc.2026.104986. Full text in Research Archive
Gissum, Karen; Engen, Caroline Benedicte Nitter; Drageset, Sigrunn; Eriksson, Ane Gerda Zahl; Vistad, Ingvild & Strand, Roger [Show all 7 contributors for this article] (2026). Hope and hopelessness in the face of ovarian cancer: perspectives from gynecologists. Frontiers in Oncology. 16. doi: 10.3389/fonc.2026.1931795. Full text in Research Archive Show summary
Background Effective communication plays a key role in fostering strong relationships between patients and healthcare providers during cancer treatment and care. Women with ovarian cancer live with the illness and disease aspects of the condition, while biomedical knowledge tends to focus on the disease. We aimed to gain an understanding of the patient-provider relationship in ovarian cancer from a gynecologists’ perspective. Materials and methods We collected data using semi-structured interviews and applied a phenomenological approach to data analysis. Results We conducted individual interviews with nine gynecologists between October 2022 and February 2023. Three distinctive features defined the gynecologists’ understanding (1). When interacting with patients, they focused on diagnostic markers and treatment choices, paying more attention to the disease than to holistic well-being (2). The gynecologists’ understanding of ovarian cancer was mainly based on medical knowledge rather than on patients’ experiences (3). The tragic nature of ovarian cancer led the gynecologists to create emotional distance as a means of self-preservation, while harboring a hope that medical advancements would lead to a cure in the future but acknowledging their feelings of helplessness in treating these patients. Conclusion Gynecologists understand ovarian cancer from a disease perspective of health. Their role is to maintain the biomedical dimension of condition, upholding patients’ hope as well as their own for medical advancement throughout the ovarian cancer trajectory. Furthermore, gynecologists understand their role as constrained by a rigid system that limits their ability to best provide holistic care to patients.
Bhatt, Aditi; Stepanyan, Artem; Al-Niaimi, Ahmed; Brennan, Donal; Baumgartner, Joel & Bakrin, Naoual [Show all 25 contributors for this article] (2026). Principles of cytoreductive surgery for primary and metastatic peritoneal malignancies—the PSOGI–ESGO–ISSPP Lyon consensus. The Lancet Oncology. ISSN 1470-2045. 27(4), p. e181–e194. doi: 10.1016/S1470-2045(26)00052-5. Full text in Research Archive
Ledermann, J. A.; Matias-Guiu, X.; Amant, F.; Concin, N.; Davidson, Ben & Fotopoulou, C. [Show all 46 contributors for this article] (2025). ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Annals of Oncology. ISSN 0923-7534. 35(3), p. 248–266. doi: 10.1016/j.annonc.2023.11.015. Full text in Research Archive
Wang, Yun; Nieuwenhuysen, Els Van; Rootwelt-Revheim, Mona-Elisabeth; Deroose, Christophe M.; Eriksson, Ane Gerda Zahl & Eyjólfsdóttir, Brynhildur [Show all 12 contributors for this article] (2025). First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer. Gynecologic Oncology. ISSN 0090-8258. 204, p. 158–164. doi: 10.1016/j.ygyno.2025.11.018. Full text in Research Archive Show summary
Objective The aim of this Phase 1 study was to evaluate safety and tolerability of the alpha emitting therapy 224Ra-labeled microparticles (Radspherin®) and to establish the recommended dose for further development. Methods The study was conducted in patients who had undergone complete resection of platinum-sensitive recurrent ovarian cancer. A single dose of Radspherin was administered intraperitoneally one to three days after surgery. Dose escalation (3 + 3 design) was performed at 1, 2, 4 and 7 MBq. Safety and tolerability of Radspherin after 12 months are presented. Results Fourteen patients were enrolled across the 4 dose levels. Median age was 66 (56–77) years. Median peritoneal cancer index at the start of the surgery was 7 (3–16). No dose limiting toxicity (DLT) was observed. A total of 98 treatment emergent adverse events were reported (95 grade 1 or 2, and 3 grade 3). The three grade 3 events were cases of ileus (2) and anaemia (1) and were reported as unrelated to Radspherin by the investigators. One grade 2 serious adverse event of procedural complication (disconnect syringe-catheter) was reported as related to Radspherin. At 12-months, none of the patients had experienced peritoneal disease progression. Conclusions All dose levels were well tolerated, with no DLT observed. The highest activity dose of 7 MBq was selected as recommended dose for an expansion cohort. No grade ≥ 3 adverse events related to Radspherin were reported. Clinical trial information NCT03732768
Hagen, Kristine Krüger; Lie, Agnes Kathrine; Dahl, Gunn Fallås; Eyjólfsdóttir, Brynhildur; Wang, Yun & Ranum, Petter Skauen [Show all 12 contributors for this article] (2025). The Silva pattern-based classification and oncological outcomes in women undergoing fertility-sparing surgery for early-stage cervical cancer. International Journal of Gynecological Cancer. ISSN 1048-891X. 35(9). doi: 10.1016/j.ijgc.2025.102012. Full text in Research Archive
Trent, Pernille Kristina Bjerre; Leitzinger, Nils; Wang, Yun; Dahl, Gunn Fallås; Eyjólfsdóttir, Brynhildur & Dahl, Jørgen Fallås [Show all 10 contributors for this article] (2025). The detection rate of metastatic lymph nodes comparing sentinel lymph node biopsy and lymphadenectomy for staging of intermediate- and high-risk endometrial carcinoma. International Journal of Gynecological Cancer. ISSN 1048-891X. 35(5). doi: 10.1016/j.ijgc.2025.101810. Full text in Research Archive Show summary
Objective The primary aim of this study was to compare the detection rates of nodal metastases between lymphadenectomy (LND) and sentinel lymph node (SLN) in intermediate- and high-risk patients with assumed uterine-confined disease. Methods This was a single-center observational study of patients from a tertiary referral center (2006-2023). Intermediate risk was defined as endometrioid adenocarcinoma grade 1/2 with ≥50% myoinvasion or grade 3 with <50% myoinvasion. High risk was defined as endometrioid adenocarcinoma grade 3 with ≥50% myoinvasion, non-endometrioid histologies regardless of myoinvasion or cervical involvement of any histology, and myoinvasion. All SLNs underwent pathologic ultra-staging. Nodal metastases were defined as the presence of macro- or micro-metastases. The comparison of metastatic lymph node rates by nodal assessment method was performed using the χ2 test and multivariable logistic regression analysis. Results A total of 996 patients were included (333 in the intermediate-risk group and 663 in the high-risk group). In the intermediate-risk group 192/333 (58%) patients underwent LND and 141/333 (42%) underwent SLN. Nodal metastases were detected in 11% and 9% of the LND and SLN cohorts (p = .46). Increasing proportions of staged patients were observed after SLN implementation (57% vs 78%) (p < .001). In the high-risk group, 412/663 (62%) patients underwent LND, and 251/663 (38%) underwent SLN. Nodal metastases were detected in 19% and 14% of the LND and SLN cohorts, respectively (p = .11). The majority of isolated tumor cells were observed in endometrioid histologies compared to non-endometrioid histologies (71% vs 29%, p = .01). Increasing proportions of staged patients were observed after SLN implementation (82% vs 88%) (p = .02). In the multivariable analysis, no association was observed between the nodal assessment method and the detection rates of nodal metastases in either risk group. Conclusions In this predominantly high-risk population, the implementation of an SLN algorithm did not compromise the detection of nodal metastases. As more patients are comprehensively staged after SLN implementation, we expect more accurate surgical staging and adjuvant therapy allocation in this specific patient group in the future.
Brunetti, Marta; Vitelli, Valeria; Naas, Anca Michaela; Eriksson, Ane Gerda Zahl; Haugland, Hans Kristian & Krakstad, Camilla [Show all 7 contributors for this article] (2025). Molecular Landscape of Endometrial Stromal Tumors. JCO Precision Oncology (JCO PO). 9. doi: 10.1200/PO-24-00779. Full text in Research Archive Show summary
Purpose: The molecular heterogeneity of endometrial stromal tumors (ESTs) is demonstrated by the presence of the same fusion gene in distinct pathologic entities, such as endometrial nodules and low-grade endometrial stromal sarcoma, both exhibiting the JAZ1::SUZ12 chimeric transcript. Given the limited knowledge on these tumors, which is based on a small number of cases studied with a restricted range of techniques, we analyzed 47 ESTs to explore their methylation and transcriptomic landscapes. Materials and Methods: Tumor methylation and transcriptomes profiles were investigated. Results: The methylation profile showed distinct clusters, which correlated with established histopathologic and molecular subtypes. The highest methylation value was reported for nuclear factor of activated T cytoplasmic 1, and the lowest was detected for miR34C. Two different 5'—C—phosphate—G—3' (CpG) sites of LMX1B (LMX1B-cg04996334 and LMX1B), along with miR34C, showed the same methylation pattern in both low-grade and high-grade endometrial stromal sarcoma (HG-ESS). Similarly, CFAP45, HDAC4, ACY3, MOB3A, and XXYLT1 showed identical methylation patterns in HG-ESS and undifferentiated uterine sarcomas, highlighting the similarities between these tumors within the EST spectrum. We identified 13 novel fusion transcripts involving several genes that are active in transcriptional regulation. Conclusion: In ESTs, the genes involved in chromosomal rearrangements function as transcription regulators, either directly through the formation of zinc finger motifs or indirectly through epigenetic regulation. The methylation signature is different for distinct subgroups of the EST spectrum, with more aggressive tumors, HG-ESS, and undifferentiated uterine sarcoma, clustering together. Some genes showed similar methylation levels in different entities, highlighting the presence of a continuum in the tumor profile. Methylation levels of CpG sites at specific gene loci may serve as valuable biomarkers for these tumors.
Engh, Anette; Rueegg, Corina Silvia; Trent, Pernille Kristina Bjerre; Opheim, Linn Øvstebø; Engeskaug, Ida & Nordskar, Nina Jebens [Show all 10 contributors for this article] (2025). Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study. Gynecologic Oncology. ISSN 0090-8258. 195, p. 82–88. doi: 10.1016/j.ygyno.2025.03.009. Full text in Research Archive Show summary
Objective The aims of this cross-sectional study were to describe the prevalence of self-reported lower extremity lymphedema (LEL) by different physical activity (PA) levels and to examine if higher levels of PA are associated with lower odds of self-reported LEL among endometrial cancer survivors. Methods Women treated for assumed early-stage endometrial cancer between 2006 and 2021 were invited to complete the Lower Extremity Lymphedema Screening Questionnaire (LELSQ) and the Physical Activity Frequency, Intensity, and Duration (PAFID) questionnaire. Responses of PAFID were converted into metabolic equivalent of task minutes per week (MET-min/week), and participants were categorized into different PA levels: meeting (≥500 MET-min/week) versus not meeting PA guidelines; low active (<500 MET-min/week), active (500–1000 MET-min/week), and high active (>1000 MET-min/week); and PA quartiles. Results Among 1077 included, the prevalence of LEL was 48 %, 32 %, and 32 % among the low active, active, and high active survivors, respectively. Compared to the low active, the active survivors had 40 % lower odds of LEL (OR 0.60, 95 % CI 0.44–0.81), but no further reduction was observed among the high active survivors (OR 0.71, 95 % CI 0.47–1.06). According to PA quartiles, higher PA levels were associated with lower odds of LEL, but not in a linear dose-response way. Conclusion Findings suggest that regular PA according to the current PA guidelines is associated with decreased the odds of self-reported LEL among endometrial cancer survivors; however, causality of association needs to be verified in a longitudinal setting.
Dagher, Christian; Trent, Pernille Kristina Bjerre; Alwaqfi, Rofieda; Davidson, Ben; Ellenson, Lora H. & Zhou, Qin [Show all 17 contributors for this article] (2025). Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma. International Journal of Gynecological Cancer. ISSN 1048-891X. 35(4). doi: 10.1016/j.ijgc.2025.101651. Full text in Research Archive Show summary
Objective Lymphovascular invasion can predict nodal spread and recurrence in endometrioid endometrial cancer; however, the impact of lymphovascular invasion quantification on local versus distant recurrence in surgically staged patients has not yet been established. Methods This multicenter, retrospective cohort study included surgically staged patients with International Federation of Obstetrics and Gynecology 2009 stage I node-negative endometrioid endometrial cancer. Patients were treated between January 2012 and December 2019 at 2 tertiary cancer centers. Staging included a total hysterectomy and lymph node assessment. The extent of lymphovascular invasion was defined using the World Health Organization criteria as focal (<5 vessels involved on at least 1 pathology slide) or substantial (≥5 vessels involved). Recurrence and death were considered as events. A competing risk analysis was performed and controlled for multicenter clustering. Results Overall, 1555 patients met the inclusion criteria: 65 (4.2%) had substantial invasion, 119 (7.7%) had focal, and 1371 (88.2%) had no invasion. The median follow-up was 61.5 months (range; 0.8-133.9). There were 173 evaluable events among the 1554 patients: 56 local recurrences, 43 distant recurrences, and 74 deaths without recurrence. Deep (>50%) myoinvasion and grade 3 histology were more frequently observed in patients with substantial myoinvasion. Overall, 323 patients (20.8%) received adjuvant therapy. The 5-year cumulative incidence failure rates for any recurrence were 6.0% for no, 19.5% for focal, and 19.0% for substantial invasion. Compared to no lymphovascular invasion, substantial invasion was associated with an increased risk of distant recurrence (adjusted HR 2.29, 95% CI 1.17 to 4.46). Conclusions In patients with surgical stage I endometrioid endometrial cancer, the focal and substantial lymphovascular invasion was associated with a 3-fold increased risk of cumulative incidence failure versus no lymphovascular invasion. Patients with substantial invasion had more deeply invasive and grade 3 tumors and appeared to experience more distant than local recurrences. These findings challenge the International Federation of Obstetrics and Gynecology 2023 staging classification that combines no lymphovascular invasion and focal lymphovascular invasion into a single risk category.
Dagher, Christian; Trent, Pernille Kristina Bjerre; Alwaqfi, Rofieda; Davidson, Ben; Ellenson, Lora & Zhou, Qin C [Show all 14 contributors for this article] (2024). Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study. International Journal of Gynecological Cancer. ISSN 1048-891X. 34(10), p. 1485–1492. doi: 10.1136/ijgc-2024-005746. Full text in Research Archive
Davidson, Ben; Lande, Karin Teien; Nebdal, Daniel J.H.; Nesbakken, Anne Jorun; Holth, Arild & Lindemann, Kristina Yvonne Kathe [Show all 8 contributors for this article] (2024). Endometrial carcinomas with ambiguous histology often harbor TP53 mutations. Virchows Archiv. ISSN 0945-6317. 0(0), p. 1–9. doi: 10.1007/s00428-024-03912-7. Full text in Research Archive Show summary
The objective of the present study was to characterize the molecular features of endometrial carcinomas with ambiguous histology. Eighteen carcinomas that could not be conclusively typed based on morphology and immunohistochemistry underwent analysis of mismatch repair (MMR) status, microsatellite status, and whole-exome sequencing. None of the tumors had pathogenic POLE mutation. Twelve tumors (67%) were microsatellite stable, and 6 (33%) had microsatellite instability. Fourteen tumors (78%) harbored TP53 mutations, and 2 (11%) had mutations in MMR genes. Eleven carcinomas (61%) were classified as copy number high and 7 (39%) as MSI-hypermutated, the latter including 3 tumors with TP53 mutation who concomitantly had MSI or mutation in a MMR gene. Other mutations that were found in > 1 tumor affected MUC16 (7 tumors), PIK3CA (6 tumors), PPP2R1A (6 tumors), ARID1A (5 tumors), PTEN (5 tumors), FAT1 (4 tumors), FAT4 (3 tumors), BRCA2 (2 tumors), ERBB2 (2 tumors), FBXW7 (2 tumors), MET (2 tumors), MTOR (2 tumors), JAK1 (2 tumors), and CSMD3 (2 tumors). At the last follow-up (median = 68.6 months), 8 patients had no evidence of disease, 1 patient was alive with disease, 8 patients were dead of disease, and 1 patient died of other cause. In conclusion, based on this series, the molecular landscape of endometrial carcinomas with ambiguous histology is dominated by TP53 mutations and the absence of POLE mutations, with heterogeneous molecular profile with respect to other genes. A high proportion of these tumors is clinically aggressive.
Rios-Doria, Eric; Abu-Rustum, Nadeem R; Glaser, Gretchen; McGree, Michaela; Eriksson, Ane Gerda Zahl & Pham, Melissa [Show all 12 contributors for this article] (2024). 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both. International Journal of Gynecological Cancer. ISSN 1048-891X. doi: 10.1136/ijgc-2024-005567. Full text in Research Archive
Luijten, Maartje M. W.; Weelden, Willem Jan van; Lalisang, Roy I.; Bulten, Johan; Lindemann, Kristina Yvonne Kathe & Beekhuizen, Heleen J. van [Show all 23 contributors for this article] (2024). Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma. Cancers. 16(11). doi: 10.3390/cancers16112084. Full text in Research Archive Show summary
Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0–10%, 10–50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.
Davidson, Ben; Holth, Arild; Lindemann, Kristina Yvonne Kathe; Eriksson, Ane Gerda Zahl; Nilsen, Thale Andrea & Kristensen, Annette Torgunrud (2024). Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations. Virchows Archiv. ISSN 0945-6317. 485(6), p. 1053–1061. doi: 10.1007/s00428-024-03821-9. Full text in Research Archive Show summary
Carcinosarcoma (CS) is an uncommon and clinically aggressive malignancy. The objective of the present study was to characterize the molecular features of CS at various anatomic locations, including serous effusions. Specimens (n = 32) consisted of 25 biopsies/surgical resection specimens and 7 serous effusions (6 peritoneal, 1 pleural) from 25 patients. Fresh-frozen cell pellets and surgical specimens underwent targeted next-generation sequencing covering 50 unique genes. A total of 31 mutations were found in 25 of the 32 tumors studied, of which 1 had 3 mutations, 4 had 2 different mutations, and 20 had a single mutation. The most common mutations were in TP53 (n = 25 in 24 tumors; 1 tumor with 2 different mutations), with less common mutations found in RB1 (n = 2), MET (n = 1), KRAS (n = 1), PTEN (n = 1), and KIT (n = 1). Patient-matched specimens harbored the same TP53 mutation. Tumors with no detected mutations were more common in serous effusion specimens (3/7; 43%) compared with surgical specimens (4/25; 16%). In conclusion, the molecular landscape of CS is dominated by TP53 mutations, reinforcing the observation that the majority of these tumors develop from high-grade serous carcinoma. Whether CS cells in serous effusions differ from their counterparts in solid lesions remains uncertain.
Fotopoulou, Christina; Eriksson, Ane Gerda Zahl; Planchamp, François; Morice, Philippe; Taylor, Alexandra & Sturdza, Alina [Show all 11 contributors for this article] (2024). European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management. International Journal of Gynecological Cancer. ISSN 1048-891X. 34(4). doi: 10.1136/ijgc-2024-005293. Full text in Research Archive
Cun, Han T.; Bernard, Laurence; Lande, Karin Teien; Lawson, Barrett C.; Nesbakken, Anne Jorun & Davidson, Ben [Show all 11 contributors for this article] (2024). Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecologic Oncology. ISSN 0090-8258. 189, p. 138–145. doi: 10.1016/j.ygyno.2024.07.677. Full text in Research Archive Show summary
Objective The treatment for stage IB grade 3 endometrioid endometrial adenocarcinoma is challenging with variable practice. Molecular characterization may help identify adjuvant therapy strategies beyond stage. We aimed to better understand the molecular features of these tumors by characterizing them by ProMisE classification, mutational signature, and commonly mutated genes. Methods Patients with stage IB grade 3 EEC at two institutions were included. Immunohistochemistry and whole exome sequencing were performed on archival FFPE tissue sections to determine ProMisE classification. Personal Cancer Genome Reporter was used for somatic variant annotation, and mutational signatures were generated based on COSMIC single base substitution mutational signatures. Results 46 patients were included with variable adjuvant treatment. Nine patients recurred (19.6%), most with extra-abdominal disease (n = 5, or 55.6%). 10 had POLE mutations (21.7%), 18 were MMR deficient (39.1%), 6 had abnormal p53 (13.0%), and 12 were p53 wildtype (26.1%). There were no recurrences in the POLE subgroup. A dominant mutational signature was identified in 38 patients: 17 SBS5 signature (44.7%), 10 SBS15 or SBS44 signature (26.3%), 7 SBS10a or SBS10b signature (18.4%), 3 SBS14 signature (7.9%), and 1 SBS40 signature (2.6%). The six patients that recurred had a SBS5 signature. Frequently mutated genes included ARID1A (n = 30, 65%), PTEN (n = 28, 61%), MUC16 (n = 27, 59%), and PIK3CA (n = 25, 54%). Conclusions This comprehensive evaluation found a molecularly diverse cohort of tumors, despite the same histology, stage and grade. Mutational signature SBS5 correlated with a high risk of recurrence. Further refining of endometrial cancer classification may enable more precise patient stratification and personalized treatment approaches.
Nikolova, Tanja; Bilir, Esra; Bizzarri, Nicolò; Fotopoulou, Christina; Gorp, Toon Van & Kacperczyk-Bartnik, Joanna [Show all 13 contributors for this article] (2024). Gender equality, diversity, and inclusion among gynaecologic oncologists: European Network of Young Gynae Oncologists (ENYGO)-European Society of Gynaecological Oncology (ESGO) project. International Journal of Gynecological Cancer. ISSN 1048-891X. 34(11), p. 1685–1690. doi: 10.1136/ijgc-2024-005697. Full text in Research Archive
Rios-Doria, Eric; Nobre, Silvana Pedra; Sassine, Dib; Glaser, Gretchen; Eriksson, Ane Gerda Zahl & Ataseven, Beyhan [Show all 12 contributors for this article] (2024). Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium. Gynecologic Oncology. ISSN 0090-8258. 190, p. 236–242. doi: 10.1016/j.ygyno.2024.08.019. Full text in Research Archive
Trent, Pernille Kristina Bjerre; Eriksson, Ane Gerda Zahl; Staff, Anne Cathrine; Juul-Hansen, Knut Erling; Burger, Emily Annika & Wangen, Knut Reidar (2024). A cost-effectiveness analysis of sentinel lymph node biopsy compared with lymphadenectomy in intermediate- and high-risk endometrial carcinoma. International Journal of Gynecological Cancer. ISSN 1048-891X. 35(1). doi: 10.1136/ijgc-2024-005906. Full text in Research Archive Show summary
Background Sentinel lymph node biopsy (SLN) is increasingly used for surgical staging of endometrial carcinoma. Objective To estimate the effect and cost-effectiveness of the implementation of an SLN algorithm for surgical staging in patients with intermediate- and high-risk endometrial carcinoma compared with lymphadenectomy. Methods We performed a model-based, cost-effectiveness analysis using primary data from a tertiary referral hospital that included 829 patients with endometrial carcinoma undergoing surgical staging. We quantified the health and economic outcomes from two time periods, before and after implementation of the SLN algorithm by robotic surgery. Costs were measured directly from the hospital’s financial department, while long-term health outcomes were estimated using self-reported lymphedema and health-related quality-of-life among survivors. Sensitivity analyses were conducted to evaluate uncertainty. Results We projected that the SLN implementation period, predominately reflecting use of robotic SLN, simultaneously improved health outcomes (0.08 incremental quality-adjusted life-years) and lowered costs (US$1051) compared with the prior period involving robotic or open lymphadenectomy. SLN remained more beneficial and less costly across key sensitivity analyses—namely, varying the cost of the robotic platform, surgical equipment, number of yearly robotic procedures, percentage of robotic procedures versus percentage of laparotomies, length of stay, and lymphedema development. After 1000 simulations of the model, SLN implementation provided greater health benefits for lower costs (ie, cost saving) in 89% of simulations. Conclusion Implementation of an SLN algorithm in the staging of intermediate- and high-risk endometrial carcinoma improved health outcomes for lower costs compared with lymphadenectomy. Cost-effectiveness could further improve by continuing to increase the proportion of robotic procedures.
Trent, Pernille Kristina Bjerre; Nordskar, Nina Jebens; Wangen, Knut Reidar; Engeskaug, Ida; Opheim, Linn Øvstebø & Aune, Guro [Show all 10 contributors for this article] (2023). Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study. Gynecologic Oncology. ISSN 0090-8258. 175, p. 72–80. doi: 10.1016/j.ygyno.2023.05.070. Full text in Research Archive Show summary
Objectives Sentinel lymph node biopsy (SLN) has replaced lymphadenectomy in staging of endometrial carcinoma. The aims of the study were to explore the prevalence of self-reported lymphedema (LEL), identify factors associated with LEL, compare quality of life (QoL) scores using thresholds of clinical importance, and assess correlation between different questionnaires. Methods Women who underwent staging for endometrial carcinoma from 2006 to 2021 were invited to complete the Lower Extremity Lymphedema Screening Questionnaire (LELSQ), EORTC QLQ-C30, QLQ-EN24 and EQ-5D-5L. Results Of 2156 invited survivors, 61% participated in the study, whereof 1127 were evaluable by LELSQ. The LEL prevalence was 51%, 36% and 40% after lymphadenectomy, SLN and hysterectomy, respectively (p < 0.001). Higher BMI, undergoing lymphadenectomy and receiving adjuvant chemotherapy were associated with LEL; odds ratios 1.07 (95% CI 1.05–1.09), 1.42 (95% CI 1.03–1.97) and 1.43 (95% CI 1.08–1.89) respectively. QoL was lower for women with LEL compared to those without. In women with musculoskeletal complaints the prevalence of LEL was 59%, 50% and 53% after lymphadenectomy, SLN and hysterectomy (p = 0.115), respectively, compared to 39%, 17% and 18% (p < 0.001) in women without musculoskeletal complaints. Spearman's correlation was moderate to strong between the questionnaires. Conclusion SLN implementation is not associated with increased LEL prevalence compared to hysterectomy alone, but is associated with a significantly lower prevalence compared to lymphadenectomy. LEL is associated with lower QoL. Our study demonstrates moderate to strong correlation between self-reported LEL and QoL scores. Available questionnaires may not distinguish between symptoms caused by LEL and musculoskeletal disease.
Fotopoulou, Christina; Eriksson, Ane Gerda Zahl; Yagel, Itai; Chang, Suk-Joon & Lim, Myong Cheol (2023). Surgery for Recurrent Epithelial Ovarian Cancer. Current Oncology Reports. ISSN 1523-3790. doi: 10.1007/s11912-023-01480-8. Full text in Research Archive
Opheim, Linn Øvstebø; Engeskaug, Ida; Trent, Pernille Kristina Bjerre; Thorsen, Lene; Staff, Anne Cathrine & Nordskar, Nina Jebens [Show all 9 contributors for this article] (2023). Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional study. Gynecologic Oncology. ISSN 0090-8258. 179, p. 52–62. doi: 10.1016/j.ygyno.2023.10.012. Full text in Research Archive Show summary
Objective To explore possible associations between modifiable lifestyle factors and health-related quality of life (HRQoL) in endometrial carcinoma survivors by assessing differences in HRQoL between survivors meeting and not meeting the World Health Organization's (WHO) recommendations regarding physical activity, BMI, and smoking. Methods This was a cross-sectional population-based study in women having undergone surgery for assumed early-stage endometrial carcinoma. Thresholds for clinical importance based on the EORTC QoL working group were used to interpret scores. Effect size (ES) was interpreted as small (d = 0.2–0.49), medium (d = 0.5–0.8), and large (d > 0.8). Results In total, 1200 evaluable women were included. Meeting physical activity recommendations and BMI <25 kg/m2 was associated with significantly better global health status, (ES) = 0.18 and ES = −0.11, respectively. On multivariate analysis, women meeting physical activity recommendations had significantly higher scores on physical- (ES = 0.31), role- (ES = 0.15), and social functioning (ES = 0.15), and lower levels of fatigue (ES = −0.16), pain (ES = −0.10), and appetite loss (ES = −0.15) (all p < 0.05) compared to non-meeting survivors. Participants with BMI ≥25 kg/m2 had lower scores for social functioning (ES = −0.10), and higher levels of pain (ES = 0.13) and dyspnea (ES = 0.12) (all p < 0.05) compared to those with BMI <25 kg/m2. Smokers had lower scores for emotional functioning (ES = −0.09) and higher levels of diarrhea (ES = 0.10) (all p < 0.05) compared to non-smokers. Conclusion Meeting WHO recommendations for modifiable life-style factors is associated with better HRQoL among endometrial carcinoma survivors: Being sufficiently physical active and having a BMI <25 kg/m2 are significantly associated with better self-reported global health status. All modifiable factors are associated with better functioning, and reduced symptom-burden.
Trent, Pernille Kristina Bjerre; Falk, Ragnhild Sørum; Staff, Anne Cathrine; Jorde, Doris & Eriksson, Ane Gerda Zahl (2023). Translation and cross-cultural adaptation of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire. International Journal of Gynecological Cancer. ISSN 1048-891X. 33(2), p. 231–235. doi: 10.1136/ijgc-2022-003979. Full text in Research Archive Show summary
Objective There is a paucity of international data regarding self-reported lower extremity lymphedema and quality of life after surgery for gynecological cancer. Validated questionnaires are emerging, but translated versions are lacking. Cross-cultural adaptation is important to reduce the risk of introducing bias into a study. Objective To translate and culturally adapt the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire for a Norwegian population. Methods Permission to use the original English versions of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire for translation was obtained. The questionnaires were translated using a procedure based on standard guidelines, including forward translation by native speakers of the target language, synthesis, back translation, and review. Seventeen patients from the Norwegian Radium Hospital gynecological cancer outpatient clinic, all expected to have stable disease, were invited for questionnaire test–retest by completing the same questionnaires twice at 3–4-week intervals. Internal consistency was assessed by calculating Cronbach’s alpha. Test–retest reliability was assessed using an intra-class correlation coefficient. Results Twelve patients completed the questionnaires twice. Cronbach’s alpha was 0.75 for the Gynecologic Cancer Lymphedema Questionnaire and 0.89 for the Lower Extremity Lymphedema Screening Questionnaire. The intra-class correlation coefficient was 0.86 for the Gynecologic Cancer Lymphedema Questionnaire and 0.91 for the Lower Extremity Lymphedema Screening Questionnaire. Conclusions Translation and cross-cultural adaptation of these internationally validated patient-reported outcomes questionnaires for survivors of lower extremity lymphedema in gynecological cancer was feasible. The Norwegian translation of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire showed acceptable internal consistency and the test–retest reliability was excellent.
Bilir, Esra; Ahmed, Wasim; Kacperczyk-Bartnik, Joanna; Nasser, Sara; Trent, Pernille Kristina Bjerre & Boria, Felix [Show all 14 contributors for this article] (2023). Social media ambassadors and collaboration with OncoAlert: A European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022. International Journal of Gynecological Cancer. ISSN 1048-891X. 2023(33), p. 964–970. doi: 10.1136/ijgc-2023-004371. Full text in Research Archive
Kurnit, Katherine C.; Nobre, Silvana Pedra; Fellman, Bryan M.; Iglesias, David A.; Lindemann, Kristina Yvonne Kathe & Jhingran, Anuja [Show all 12 contributors for this article] (2022). Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. Gynecologic Oncology. ISSN 0090-8258. doi: 10.1016/j.ygyno.2022.09.025. Full text in Research Archive
Brunetti, Marta; Panagopoulos, Ioannis; Vitelli, Valeria; Andersen, Kristin; Hveem, Tarjei Sveinsgjerd & Davidson, Ben [Show all 10 contributors for this article] (2022). Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile. Cancers. 14:3536(14), p. 1–16. doi: 10.3390/cancers14143536. Full text in Research Archive Show summary
Simple Summary Endometrial carcinomas (ECs), the most frequent type of uterine body cancer, are highly heterogeneous with overlapping clinical, pathological, and molecular features. This study aimed to gain insights into these cancers’ chromosomal and genomic aberration patterns as well as their gene and miRNA expression profiles, all of which are both pathogenetically and clinically important disease features. We found that chromosome 1 was the most frequently rearranged chromosome, mostly leading to gain of 1q, that the genes PTEN, PDGFRA, PIK3CA, and KIT were the most frequent pathogenic variants, and that some other genes and miRNAs of known importance in carcinogenesis and the immune response showed consistent deregulation. This study confirms that a high degree of genetic heterogeneity characterizes EC tumors but highlights the nonrandom involvement of some loci. Abstract Endometrial carcinomas (ECs) are histologically classified as endometrioid and nonendometrioid tumors, with each subgroup displaying different molecular profiles and clinical outcomes. Considerable biological and clinical heterogeneity exists within this scheme, however, reflecting its imperfection. We aimed to gather additional data that might help clarify the tumors’ pathogenesis and contribute toward a more meaningful classification scheme. In total, 33 ECs were examined for the presence of chromosomal aberrations, genomic imbalances, pathogenic variants, microsatellite instability, and expression profiles at both gene and miRNA levels. Chromosome 1 was the most frequently rearranged chromosome, showing a gain of all or part of the long arm. Pathogenic variants were found for PTEN (53%), PDGFRA (37%), PIK3CA (34%), and KIT (31%). High microsatellite instability was identified in 15 ECs. Comparing tumors and controls, we identified 23 differentially expressed genes of known importance in carcinogenesis, 15 genes involved in innate and adaptative immune responses, and altered expression of 7 miRNAs. miR-32-5p was the most upregulated. Our series showed a high degree of heterogeneity. Tumors were well-separated from controls, but there was no clear-cut separation between endometrioid and nonendometrioid ECs. Whether this means that the current phenotypic classification is of little relevance or if one still has not detected which genomic parameters to enter into correlation analyses remains unknown. Keywords: endometrial carcinoma; karyotype; chromosome 1; mutation analysis; microsatellite instability; gene expression; cancer pathways; cancer immune profile; miRNA
Daviu, Cristina; Blaakaer, Jan; Eriksson, Ane Gerda Zahl; Herrstedt, Jørn; Vandborg, M.P. & Rasmussen, Anne Mette Odgaard [Show all 7 contributors for this article] (2022). Nonepithelial ovarian cancer–the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO). Acta Oncologica. ISSN 0284-186X. 61(8), p. 939–945. doi: 10.1080/0284186X.2022.2088249. Full text in Research Archive
Lanner, Maximilian; Nikolova, Tanja; Gutic, Bojana; Nikolova, Natasha; Pletnev, Andrei & Selcuk, Ilker [Show all 40 contributors for this article] (2021). Subspecialty training in Europe: A report by the European Network of Young Gynaecological Oncologists. International Journal of Gynecological Cancer. ISSN 1048-891X. 31(4), p. 575–584. doi: 10.1136/ijgc-2020-002176. Full text in Research Archive
Davidson, Ben; Kleinberg, Lilach; Børresen, Ida Marie; Slettevoll, Frøydis; Fangberget, Anne & Hindosh, Dunia [Show all 8 contributors for this article] (2021). Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis. Virchows Archiv. ISSN 0945-6317. 479, p. 419–424. doi: 10.1007/s00428-021-03057-x. Full text in Research Archive Show summary
Abstract Ectomesenchymoma is an exceedingly rare biphasic malignant tumor characterized by the presence of mesenchymal and neuroectodermal elements. The majority of patients are infants or children. We describe the first case of this entity diagnosed as a primary uterine tumor. A 72-year-old female presented with post-menopausal bleeding. Dilatation and curettage showed irregular mesenchymal proliferation of uncertain nature. In the hysterectomy specimen, a myxoid spindle cell tumor with areas of skeletal muscle and neural differentiation was found in the uterus, with direct invasion of the small intestine, and biphasic differentiation into rhabdomyosarcoma and ganglioneuroblastoma was unequivocally seen in a lymph node metastasis. The morphological findings were validated by immunohistochemistry. Massive parallel sequencing identified TP53 , PTEN , and DICER1 mutations in the tumor. This report describes the presence of ectomesenchymoma in an unusual primary organ and in an uncharacteristic age and presents novel data regarding the genetic characteristics of this tumor.
Weelden, Willem Jan van; Lalisang, Roy I; Bulten, Johan; Lindemann, Kristina Yvonne Kathe; Beekhuizen, Heleen J. van & Trum, Hans [Show all 26 contributors for this article] (2021). Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. American Journal of Obstetrics and Gynecology. ISSN 0002-9378. 225(4). doi: 10.1016/j.ajog.2021.05.007. Full text in Research Archive Show summary
Background Approximately 20% of women with endometrial cancer have advanced-stage disease or suffer from a recurrence. For these women, prognosis is poor, and palliative treatment options include hormonal therapy and chemotherapy. Lack of predictive biomarkers and suboptimal use of existing markers for response to hormonal therapy have resulted in overall limited efficacy. Objective This study aimed to improve the efficacy of hormonal therapy by relating immunohistochemical expression of estrogen and progesterone receptors and estrogen receptor pathway activity scores to response to hormonal therapy. Study Design Patients with advanced or recurrent endometrial cancer and available biopsies taken before the start of hormonal therapy were identified in 16 centers within the European Network for Individualized Treatment in Endometrial Cancer and the Dutch Gynecologic Oncology Group. Tumor tissue was analyzed for estrogen and progesterone receptor expressions and estrogen receptor pathway activity using a quantitative polymerase chain reaction–based messenger RNA model to measure the activity of estrogen receptor–related target genes in tumor RNA. The primary endpoint was response rate defined as complete and partial response using the Response Evaluation Criteria in Solid Tumors. The secondary endpoints were clinical benefit rate and progression-free survival. Results Pretreatment biopsies with sufficient endometrial cancer tissue and complete response evaluation were available in 81 of 105 eligible cases. Here, 22 of 81 patients (27.2%) with a response had estrogen and progesterone receptor expressions of >50%, resulting in a response rate of 32.3% (95% confidence interval, 20.9–43.7) for an estrogen receptor expression of >50% and 50.0% (95% confidence interval, 35.2–64.8) for a progesterone receptor expression of >50%. Clinical benefit rate was 56.9% for an estrogen receptor expression of >50% (95% confidence interval, 44.9–68.9) and 75.0% (95% confidence interval, 62.2–87.8) for a progesterone receptor expression of >50%. The application of the estrogen receptor pathway test to cases with a progesterone receptor expression of >50% resulted in a response rate of 57.6% (95% confidence interval, 42.1–73.1). After 2 years of follow-up, 34.3% of cases (95% confidence interval, 20–48) with a progesterone receptor expression of >50% and 35.8% of cases (95% confidence interval, 20–52) with an estrogen receptor pathway activity score of >15 had not progressed. Conclusion The prediction of response to hormonal treatment in endometrial cancer improves substantially with a 50% cutoff level for progesterone receptor immunohistochemical expression and by applying a sequential test algorithm using progesterone receptor immunohistochemical expression and estrogen receptor pathway activity scores. However, results need to be validated in the prospective Prediction of Response to Hormonal Therapy in Advanced and Recurrent Endometrial Cancer (PROMOTE) study.
Bhandoria, Geetu Prakash; Nair, Navya; Jones, Sadie Esme Fleur; Eriksson, Ane Gerda Zahl; Hsu, Heng-Cheng & Noll, Florencia [Show all 7 contributors for this article] (2021). International Gynaecological Cancer Society (IGCS) 2020 Annual Global Meeting: Twitter activity analysis. International Journal of Gynecological Cancer. ISSN 1048-891X. 31(11), p. 1453–1458. doi: 10.1136/ijgc-2021-002781. Full text in Research Archive
Eriksson, Ane Gerda Zahl; Davidson, Ben; Trent, Pernille Kristina Bjerre; Eyjólfsdóttir, Brynhildur; Dahl, Gunn Fallås & Wang, Yun [Show all 7 contributors for this article] (2021). Update on sentinel lymph node biopsy in surgical staging of endometrial carcinoma. Journal of Clinical Medicine. 10:3094(14), p. 1–11. doi: 10.3390/jcm10143094. Full text in Research Archive Show summary
Sentinel lymph node (SLN) biopsy has emerged as an alternative staging approach in women with assumed early-stage endometrial carcinoma. Through image-guided surgery and pathologic ultrastaging, the SLN approach is introducing “precision medicine” to the surgical management of gynecologic cancers, providing a comprehensive evaluation of high-yield lymph nodes. This approach improves the surgeons’ ability to detect small-volume metastatic disease while reducing intraoperative and postoperative morbidity associated with lymphadenectomy. Although the majority of clinicians in Europe and the USA have recognized the value of SLN biopsy in endometrial carcinoma and introduced this as part of clinical practice, there is ongoing debate regarding its role in very low-risk patients as well as in patients at high risk of nodal metastasis. The significance of low-volume metastasis is not fully understood, and there is no consensus in regard to how the presence of isolated tumor cells should guide adjuvant therapy. Standardized protocols for histopathologic evaluation of SLNs are lacking. In this review article we aim to provide a framework for the introduction of SLN biopsy in endometrial cancer, give an updated overview of the existing literature, as well as discuss potential controversies and unanswered questions regarding this approach and future directions.
Hage, Jos van der; Sandrucci, Sergio; Audisio, Riccardo; Wyld, Lynda; Søreide, Kjetil & Amaral, Teresa [Show all 32 contributors for this article] (2021). The ESSO core curriculum committee update on surgical oncology. European Journal of Surgical Oncology. ISSN 0748-7983. 47(11). doi: 10.1016/j.ejso.2021.10.003. Full text in Research Archive Show summary
Introduction Surgical oncology is a defined specialty within the European Board of Surgery within the European Union of Medical Specialists (UEMS). Variation in training and specialization still occurs across Europe. There is a need to align the core knowledge needed to fulfil the criteria across subspecialities in surgical oncology. Material and methods The core curriculum, established in 2013, was developed with contributions from expert advisors from within the European Society of Surgical Oncology (ESSO), European Society for Radiotherapy and Oncology (ESTRO) and European Society of Medical Oncology (ESMO) and related subspeciality experts. Results The current version reiterates and updates the core curriculum structure needed for current and future candidates who plans to train for and eventually sit the European fellowship exam for the European Board of Surgery in Surgical Oncology. The content included is not intended to be exhaustive but, rather to give the candidate an idea of expectations and areas for in depth study, in addition to the practical requirements. The five elements included are: Basic principles of oncology; Disease site specific oncology; Generic clinical skills; Training recommendations, and, lastly; Eligibility for the EBSQ exam in Surgical Oncology. Conclusions As evidence-based care for cancer patients evolves through research into basic science, translational research and clinical trials, the core curriculum will evolve, mature and adapt to deliver continual improvements in cancer outcomes for patients.
Eriksson, Ane Gerda Zahl & Mueller, Jennifer J. (2021). Advances in management of nonendometrioid endometrial carcinoma, with an emphasis on the sentinel lymph node technique. Current Opinion in Oncology. ISSN 1040-8746. 33(5), p. 457–463. doi: 10.1097/CCO.0000000000000777. Full text in Research Archive
Cibula, David; Planchamp, François; Fischerova, Daniela; Fotopoulou, Christina; Kohler, Christhardt & Landoni, Fabio [Show all 17 contributors for this article] (2020). European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. International Journal of Gynecological Cancer. ISSN 1048-891X. 30(1), p. 3–14. doi: 10.1136/ijgc-2019-000878. Full text in Research Archive Show summary
Background Optimizing and ensuring the quality of surgical care is essential to improve the management and outcome of patients with cervical cancer. To develop a list of quality indicators for surgical treatment of cervical cancer that can be used to audit and improve clinical practice. Methods Quality indicators were developed using a four-step evaluation process that included a systematic literature search to identify potential quality indicators, in-person meetings of an ad hoc group of international experts, an internal validation process, and external review by a large panel of European clinicians and patient representatives. Results Fifteen structural, process, and outcome indicators were selected. Using a structured format, each quality indicator has a description specifying what the indicator is measuring. Measurability specifications are also detailed to define how the indicator will be measured in practice. Each indicator has a target which gives practitioners and health administrators a quantitative basis for improving care and organizational processes. Discussion Implementation of institutional quality assurance programs can improve quality of care, even in high-volume centers. This set of quality indicators from the European Society of Gynaecological Cancer may be a major instrument to improve the quality of surgical treatment of cervical cancer.
Falconer, Henrik; Palsdottir, Kolbrun; Stalberg, Karin; Dahm-Kahler, Pernilla; Ottander, Ulrika & Lundin, Evelyn Serreyn [Show all 13 contributors for this article] (2019). Robot-assisted approach to cervical cancer (RACC): An international multi-center, open-label randomized controlled trial. International Journal of Gynecological Cancer. ISSN 1048-891X. 29(6), p. 1072–1076. doi: 10.1136/ijgc-2019-000558. Full text in Research Archive
Lecuru, Fabrice R; McCormack, Mary; Hillemanns, Peter; Anota, Amelie; Leitao, Mario & Mathevet, Patrice [Show all 13 contributors for this article] (2019). SENTICOL III: An international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study. International Journal of Gynecological Cancer. ISSN 1048-891X. 29(4), p. 829–834. doi: 10.1136/ijgc-2019-000332. Full text in Research Archive
Schlappe, Brooke A.; Weaver, Amy L.; Ducie, Jennifer A.; Eriksson, Ane Gerda Zahl; Dowdy, Sean C. & Cliby, William A. [Show all 13 contributors for this article] (2018). Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy. Gynecologic Oncology. ISSN 0090-8258. 151(2), p. 235–242. doi: 10.1016/j.ygyno.2018.08.022. Full text in Research Archive
Agostini, Antonio; Brunetti, Marta; Davidson, Ben; Tropé, Claes Gøran; Eriksson, Ane Gerda Zahl & Heim, Sverre [Show all 8 contributors for this article] (2018). The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas. Scientific Reports. 8. doi: 10.1038/s41598-018-29332-7. Full text in Research Archive Show summary
Different microRNAs are dysregulated in ovarian cancer where some of them have proved to be valid biomarkers. miRNA profiling analyses have shown that the different histotypes of ovarian carcinoma display differential expression of specific miRNAs. In the present study, we used miRNA-sequencing and Real-Time qPCR to detect the expression levels of miRNAs belonging to the miRNA-192/215 family, namely miR-192, miR-194, and miR-215, in different types of ovarian neoplasia, finding that miR-192, miR-194, and miR-215 were upregulated in ovarian carcinomas of the mucinous subtype, but downregulated in other types of carcinoma and in sex cord-stromal tumors. The expression of the said miRNAs was 6-fold higher in mucinous tumors compared to the other histotypes making them candidates for a possible role as diagnostic biomarkers.
Eriksson, Ane Gerda Zahl; Graul, Ashley; Yu, Miao C.; Halko, Anthony; Chi, Dennis S. & Zivanovic, Oliver [Show all 11 contributors for this article] (2017). Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. Gynecologic Oncology. ISSN 0090-8258. 146(2), p. 263–267. doi: 10.1016/j.ygyno.2017.05.022. Full text in Research Archive
Ducie, Jennifer A.; Eriksson, Ane Gerda Zahl; Ali, Narisha; McGree, Michaela E.; Weaver, Amy L. & Bogani, Giorgio [Show all 14 contributors for this article] (2017). Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecologic Oncology. ISSN 0090-8258. 147(3), p. 541–548. doi: 10.1016/j.ygyno.2017.09.030. Full text in Research Archive
Eriksson, Ane Gerda Zahl; Tropé, Claes Gøran; Kærn, Janne & Davidson, Ben (2013). A multidisciplinary approach to dagnosis and treatment of borderline ovarian tumors. In Odunsi, K; Pejovic, T & Thomas, C. (Ed.), Gynecologic Cancers. A Multidisciplinary Approach to Diagnosis and Management. Demos Medical Publishing. ISSN 9781936287895. Full text in Research Archive
Staff, Anne Cathrine; Trovik, Jone; Eriksson, Ane Gerda Zahl; Wik, Elisabeth; Wollert, Kai C. & Kempf, Tibor [Show all 7 contributors for this article] (2011). Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clinical Cancer Research. ISSN 1078-0432. 17(14), p. 4825–4833. doi: 10.1158/1078-0432.CCR-11-0715. Full text in Research Archive

View all works in NVA

Trent, Pernille Kristina Bjerre; Nordskar, Nina Jebens; Wangen, Knut Reidar; Engeskaug, Ida; Opheim, Linn Øvstebø & Aune, Guro [Show all 10 contributors for this article] (2024). Corrigendum to “Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study” [Gynecologic Oncology 175 (2023) 72–80, (S0090825823003232), (10.1016/j.ygyno.2023.05.070)]. Gynecologic Oncology. ISSN 0090-8258. 183, p. 7–8. doi: 10.1016/j.ygyno.2024.02.026. Full text in Research Archive
Fotopoulou, Christina; Eriksson, Ane Gerda Zahl; Baiocchi, Glauco & Zivanovic, Oliver (2024). Surgery for gynecological cancers in the era of personalized medicine: a novel paradigm. International Journal of Gynecological Cancer. ISSN 1048-891X. 34(3), p. 351–351. doi: 10.1136/ijgc-2024-005299. Full text in Research Archive
Eriksson, Ane Gerda Zahl (2023). Kacperczyk-Bartnik J, Bilir E, Nasser S, Strojna A, Eriksson AGZ (2023) Is it possible to block cancer? The example of #VaginalCancer on Instagram Int J Gynecol Cancer, 33 (9), 1488-1489 DOI 10.1136/ijgc-2023-004844, PubMed 37591610. International Journal of Gynecological Cancer. ISSN 1048-891X. 33(9), p. 1488–1489. doi: 10.1136/ijgc-2023-004844. Full text in Research Archive
Ramirez, Pedro T; Chiva, Luis; Eriksson, Ane Gerda Zahl; Frumovitz, Michael; Fagotti, Anna & Martin, Antonio Gonzalez [Show all 8 contributors for this article] (2020). COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers. International Journal of Gynecological Cancer. ISSN 1048-891X. 30(5), p. 561–563. doi: 10.1136/ijgc-2020-001419. Full text in Research Archive
Falconer, Henrik; Eriksson, Ane Gerda Zahl & Rudnicki, Martin (2020). Is robot-assisted laparoscopy safe for surgical treatment of cervical cancer? Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 99(1), p. 5–6. doi: 10.1111/aogs.13766. Full text in Research Archive
Eriksson, Ane Gerda Zahl; Dahl, Gunn Fallås; Nesbakken, Anne Jorun; Lund, Kjersti Vassmo & Amant, Frédéric (2019). Endometrial cancer during pregnancy: Management strategies. International Journal of Gynecological Cancer. ISSN 1048-891X. 29(7), p. 1221–1224. doi: 10.1136/ijgc-2019-000756. Full text in Research Archive
Ringerike, Tove; Samdal, Kristian; Lyngstadaas, Anita; Johansen, Karianne; Heimstad, Runa & Tuveng, Jon [Show all 9 contributors for this article] (2009). Misoprostol ved igangsetting av fødsel. Folkehelseinstituttet. ISSN 9788281212541. Full text in Research Archive Show summary
1-PAGE KEY MESSAGES *** BACKGROUND Approximately 55 000 children are born in Norway each year. It is sometimes necessary to induce labour artificially. With respect to induction with drugs, misoprostol and dinoprostone are used irrespective of whether the cervix is mature or not, while oxytocin only is used when the cervix is mature. The Norwegian Board of Health Supervision asked The Norwegian Knowledge Centre for the health Services to systematically review the efficacy and safety of misoprostol for induction of labour. METHOD This report is an overview of systematic reviews. We performed systematic searches in Cochrane Library, CRD and Ovid Medline and Embase. All included publications were evaluated for quality. In addition, we evaluated the quality of the evidence and the strength of recommendations for selected outcomes. We also performed an evaluation of legal aspects regarding the use of misoprostol for induction of labour. RESULTS Five systematic reviews met our inclusion criteria. In the systematic reviews misoprostol was given vaginally, orally, sublingually or buccally. Misoprostol was used in different dosages and dosage intervals from study to study. Our main findings were that vaginal and oral misoprostol was at least as effective as dinoprostone in inducing labour within 24 hours. However, it may have increased frequency of adverse events such as uterine hyperstimulation both without and with changes in fetal heart rate. CONCLUSION It may appear that safety is more sensitive to the dose of misoprostol than efficacy. For sublingual and buccal administration of misoprostol the amount of data were limited and we were not able to conclude on efficacy and safety.

View all works in NVA

Published June 15, 2021 2:47 PM - Last modified Oct. 10, 2023 1:37 PM